Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

M&A Buzz In Korea: CJ HealthCare On the Block

Executive Summary

CJ Group plans to sell its healthcare affiliate, in what could potentially emerge as the first major M&A deal involving a South Korean pharma firm in recent years. Although the company has not ruled out the option of an initial public offering as an alternative, the sale plan possibly reflects the changing dynamics in the Korean pharma industry.

You may also be interested in...



Can Daewoong’s P-CAB Unsettle Competition?

Daewoong Pharmaceutical has successfully completed a Phase III clinical trial of next generation gastroesophageal reflux disease (GERD) drug candidate in South Korea, but strong competition awaits from approved P-CAB drugs of CJ Healthcare and Takeda.

Kolmar Korea Eyes Pharma Expansion Via CJ HealthCare Acquisition

The acquisition of mid-size South Korean pharma firm CJ HealthCare is set to boost Kolmar Korea's pharma business, enabling the cosmetics and pharma company to transform into a larger and more integrated healthcare firm.

Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence

Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099821

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel